8-K: Protagenic Faces Nasdaq Delisting Risk Amid Delayed 10-Q, Auditor Change

Protagenic Therapeutics received a Nasdaq non-compliance notice for its delayed Q2 2025 filing and changed auditors, while also announcing progress in its PT00114 Phase I clinical trial.

Summary

• Received a notice from Nasdaq on August 20, 2025, regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
• The delay is attributed to finalizing merger-related consolidation of financial statements, including purchase accounting adjustments, pro forma financial information, and related disclosures.
• Dismissed MaloneBailey, LLP as its independent registered public accounting firm and engaged Green Growth CPAs on August 7, 2025.
• MaloneBailey's report for the fiscal year ended December 31, 2024, included an explanatory paragraph about substantial doubt regarding the company's ability to continue as a going concern.
• Completed first dose injection for all study subjects in the multiple-dose portion of its Phase I clinical trial for PT00114.
• Expects to complete dosing for PT00114 by the end of August 2025, with topline safety data anticipated by the end of September 2025.
• Plans to advance PT00114 into Phase 2 efficacy studies in the first quarter of 2026.

Sentiment

Score: 4

Explanation: While there is positive news regarding clinical trial progress, the significant issues of Nasdaq non-compliance, delayed financial reporting, and the former auditor's going concern warning create substantial negative sentiment and uncertainty for investors.

Positives

• Completed first dose injection for all study subjects in the multiple-dose portion of the Phase I clinical trial for PT00114.
• Anticipates completing dosing for PT00114 by the end of August 2025.
• Expects topline safety data for PT00114 by the end of September 2025.
• Plans to advance PT00114 into Phase 2 efficacy studies in the first quarter of 2026.
• The Nasdaq notice does not immediately affect the listing or trading of the company's securities.

Negatives

• Received a Nasdaq notice of non-compliance for failing to timely file its Form 10-Q for the quarter ended June 30, 2025.
• The previous auditor, MaloneBailey, LLP, included an explanatory paragraph in its December 31, 2024 report regarding substantial doubt about the company's ability to continue as a going concern.
• The delay in filing the Form 10-Q is due to complex merger-related financial statement consolidation.

Risks

• Risk of delisting from Nasdaq if the company fails to regain compliance with listing rules.
• Uncertainty regarding the definitive timing of filing the Form 10-Q.
• No assurance that Nasdaq will grant relief from delisting or that the company can agree to or ultimately meet applicable Nasdaq requirements for any such relief.
• Substantial doubt about the company's ability to continue as a going concern, as noted by the former auditor.
• Inherent risks and uncertainties associated with forward-looking statements, including clinical trial outcomes and regulatory approvals.

Future Outlook

The company expects to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, in the near future and intends to submit a plan to regain Nasdaq compliance within 60 calendar days. It anticipates completing dosing for its PT00114 Phase I clinical trial by the end of August 2025, with topline safety data expected by the end of September 2025, supporting advancement into Phase 2 efficacy studies planned for the first quarter of 2026.

Management Comments

• "The Company expects to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the Form 10-Q) in the near future."
• "The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter."
• "The Company expects to complete dosing by the end of August, with topline safety data anticipated by the end of September, supporting advancement into Phase 2 efficacy studies planned for the first quarter of 2026."
• "While the Company anticipates this delay to be brief, there can be no assurance as to the definitive timing of the filing."
• "The Company expects to regain compliance promptly upon filing."

Industry Context

The biotechnology and pharmaceutical industry frequently experiences delays in financial reporting due to complex accounting for mergers and acquisitions, as well as the inherent uncertainties and timelines associated with clinical trial development. Nasdaq's strict listing rules ensure transparency and financial stability, making compliance a critical factor for investor confidence in this sector. The progress in the PT00114 clinical trial, despite the financial reporting issues, highlights the dual focus of biotech companies on both operational milestones and regulatory adherence.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, uncertainty regarding financial health due to delayed reporting and going concern warning, but potential upside from clinical trial progress.
• Investors: May view the company with caution due to compliance issues and financial uncertainties, potentially impacting stock price and investment decisions.
• Regulatory Authorities (Nasdaq, SEC): Will monitor the company's progress in regaining compliance and timely filing of financial reports.

Next Steps

• File the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, in the near future.
• Submit a plan to Nasdaq to regain compliance within 60 calendar days of August 20, 2025.
• Complete dosing for the PT00114 Phase I clinical trial by the end of August 2025.
• Release topline safety data for PT00114 by the end of September 2025.
• Advance PT00114 into Phase 2 efficacy studies in the first quarter of 2026.

Key Dates

Recommendation

The combination of a Nasdaq non-compliance notice, a delayed Form 10-Q filing due to complex merger accounting, and a prior auditor's 'going concern' warning creates significant financial and operational uncertainty. While clinical trial progress for PT00114 is positive, these fundamental governance and financial reporting issues overshadow any potential upside, indicating substantial risk to the company's listing status and long-term viability. A seasoned investor would likely view these as strong indicators to exit or avoid the stock until these critical issues are definitively resolved and financial stability is demonstrated.

Keywords

Protagenic Therapeutics, PTIX, Nasdaq compliance, Form 10-Q delay, Auditor change, MaloneBailey, Green Growth CPAs, PT00114, Phase I clinical trial, Biotechnology, Pharmaceuticals, SEC filing, Going concern, Delisting risk